What clinical trials have tested Aimovig (erenumab)?
Aimovig (erenumab) was studied in multiple clinical trials to evaluate its ability to prevent migraine and reduce migraine-related symptoms. The company’s trial program included large, randomized, placebo-controlled studies in people with episodic migraine and in people with chronic migraine, as well as supporting studies that looked at durability of response and safety over time.
What outcomes were measured in Aimovig migraine-prevention trials?
Across Aimovig studies, trial endpoints typically focused on migraine frequency and related outcomes, such as changes from baseline in the number of migraine days and measures of how well patients’ migraines were controlled during the study period. Trials also tracked adverse events and discontinuations to establish safety.
How long were the Aimovig trials, and when did results show up?
In migraine-prevention programs like Aimovig’s, patients are usually treated for several months, and outcomes are assessed over repeated monthly intervals. Many anti–CGRP monoclonal antibody trials report improvements as early as the first treatment month, with more stable assessment over subsequent months to confirm consistency and durability of effect.
Who were the participants—episodic vs. chronic migraine?
Aimovig’s development included both:
- Episodic migraine populations (patients with fewer monthly migraine days), and
- Chronic migraine populations (patients who met criteria for 15 or more headache days per month, with migraine features on at least a portion of those days).
This matters because trial eligibility, baseline risk, and expected magnitude of benefit differ between episodic and chronic migraine.
What did Aimovig trials find on migraine frequency and symptom control?
Overall, Aimovig trials demonstrated that patients receiving erenumab had fewer migraine days compared with placebo, along with improvements in patient-reported measures tied to migraine burden. Safety monitoring in these programs also evaluated injection-site reactions and broader adverse events.
What safety signals were tracked in Aimovig trials?
Safety monitoring in Aimovig trials focused on:
- Adverse events and serious adverse events,
- Injection-site reactions,
- Discontinuations due to adverse events,
- Any events of special interest identified during development.
Real-world safety questions later also tend to focus on class and mechanism-related effects, but the trial program established the baseline safety profile used for labeling.
Are there newer Aimovig trials beyond the original migraine-prevention studies?
After initial approval, companies and researchers typically continue with studies that may include longer-term follow-up, additional dosing evaluations, and studies in other migraine-related settings. The exact scope depends on the trial registry entries and sponsor updates for Aimovig.
Where can I find the specific Aimovig trial IDs and study details?
For a quick way to locate trial listings (including sponsor, endpoints, and study duration), use clinical trial registries such as ClinicalTrials.gov. If you want, tell me whether you’re looking for episodic migraine, chronic migraine, or long-term follow-up, and I can point you to the most relevant Aimovig studies and what each reported.
Related: does patent/exclusivity affect ongoing Aimovig studies?
Patent status and exclusivity can influence availability of competing CGRP therapies and may shape what new trials get funded or compared against. DrugPatentWatch.com tracks patent and market-authorization details for drugs and can be a useful reference when studying the commercial landscape around Aimovig (for example, when looking at how competitors may affect trial design and enrollment). [1]
---
Sources
[1] https://www.drugpatentwatch.com/